MX2023004170A - Compuestos y oligonucleótidos derivados de n-acetilgalactosamina (galnac). - Google Patents
Compuestos y oligonucleótidos derivados de n-acetilgalactosamina (galnac).Info
- Publication number
- MX2023004170A MX2023004170A MX2023004170A MX2023004170A MX2023004170A MX 2023004170 A MX2023004170 A MX 2023004170A MX 2023004170 A MX2023004170 A MX 2023004170A MX 2023004170 A MX2023004170 A MX 2023004170A MX 2023004170 A MX2023004170 A MX 2023004170A
- Authority
- MX
- Mexico
- Prior art keywords
- galnac
- acetylgalactosamine
- oligonucleotides
- derived compounds
- symptoms
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
- C07H19/067—Pyrimidine radicals with ribosyl as the saccharide radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H1/00—Processes for the preparation of sugar derivatives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
- C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C07H21/02—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063089936P | 2020-10-09 | 2020-10-09 | |
| US202063113801P | 2020-11-13 | 2020-11-13 | |
| US202063131317P | 2020-12-29 | 2020-12-29 | |
| US202163141300P | 2021-01-25 | 2021-01-25 | |
| US202163146276P | 2021-02-05 | 2021-02-05 | |
| US202163251580P | 2021-10-01 | 2021-10-01 | |
| PCT/US2021/054318 WO2022076922A1 (en) | 2020-10-09 | 2021-10-08 | N-ACETYLGALACTOSAMINE(GAlNAc)-DERIVED COMPOUNDS AND OLIGONUCLEOTIDES |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023004170A true MX2023004170A (es) | 2023-06-27 |
Family
ID=81126164
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023004170A MX2023004170A (es) | 2020-10-09 | 2021-10-08 | Compuestos y oligonucleótidos derivados de n-acetilgalactosamina (galnac). |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20240083934A1 (https=) |
| EP (1) | EP4225322A4 (https=) |
| JP (1) | JP2023546369A (https=) |
| KR (1) | KR20230113285A (https=) |
| CN (2) | CN121108223A (https=) |
| AU (1) | AU2021359017A1 (https=) |
| CA (1) | CA3198406A1 (https=) |
| IL (1) | IL302000A (https=) |
| MX (1) | MX2023004170A (https=) |
| WO (1) | WO2022076922A1 (https=) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11649260B2 (en) | 2021-06-18 | 2023-05-16 | Hongene Biotech Corporation | Functionalized N-acetylgalactosamine nucleosides |
| EP4396193A4 (en) | 2021-08-30 | 2025-07-02 | Hongene Biotech Corp | FUNCTIONALIZED N-ACETYLGALACTOSAMINE ANALOGUES |
| JP2024546585A (ja) | 2021-12-15 | 2024-12-26 | ホンジーン バイオテック コーポレイション | 官能基化ｎ－アセチルガラクトサミンアナログ |
| JP2025517196A (ja) * | 2022-05-13 | 2025-06-03 | エーダーエックス ファーマシューティカルズ， インコーポレイテッド | 合成骨格を有するオリゴヌクレオチド及びその合成 |
| WO2024118503A1 (en) | 2022-11-28 | 2024-06-06 | Hongene Biotech Corporation | Functionalized n-acetylgalactosamine analogs |
| CN119019354B (zh) * | 2023-05-24 | 2025-07-22 | 北京炫景瑞医药科技有限公司 | 化合物及其制备方法和用途 |
| WO2024240101A1 (zh) * | 2023-05-24 | 2024-11-28 | 北京炫景瑞医药科技有限公司 | GalNAc化合物、缀合物、组合物以及它们的用途 |
| CN119019475B (zh) * | 2023-05-24 | 2026-02-06 | 北京炫景瑞医药科技有限公司 | GalNAc化合物、缀合物、组合物以及它们的用途 |
| WO2025140434A1 (zh) * | 2023-12-26 | 2025-07-03 | 成都倍特药业股份有限公司 | 一种肝靶向化合物及其在药物缀合物中的用途 |
| CN121263426A (zh) * | 2024-05-09 | 2026-01-02 | 石药集团中奇制药技术（石家庄）有限公司 | GalNAc衍生物及其寡聚核苷酸缀合物 |
| CN118638166B (zh) | 2024-08-15 | 2024-12-17 | 北京悦康科创医药科技股份有限公司 | 含有三氮唑结构的GalNAc化合物及其寡核苷酸缀合物 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6472378B2 (en) * | 1998-08-31 | 2002-10-29 | Pro-Neuron, Inc. | Compositions and methods for treatment of mitochondrial diseases |
| US6852485B1 (en) * | 2002-01-22 | 2005-02-08 | California State University Fullerton Foundation | Method for identifying a compound for the treatment of microorganism infections by inhibiting energy storage and utilization in pathogens |
| AU2009298802A1 (en) * | 2008-09-23 | 2010-04-08 | Alnylam Pharmaceuticals, Inc. | Chemical modifications of monomers and oligonucleotides with cycloaddition |
| CN111808084A (zh) * | 2008-11-10 | 2020-10-23 | 阿布特斯生物制药公司 | 用于递送治疗剂的新型脂质和组合物 |
| GB201408623D0 (en) * | 2014-05-15 | 2014-07-02 | Santaris Pharma As | Oligomers and oligomer conjugates |
| KR20180031025A (ko) * | 2015-07-31 | 2018-03-27 | 아크투루스 쎄라퓨틱스, 인크. | 약물 전달을 위한 다중 리간드 제제 |
| CA3020585A1 (en) * | 2016-04-11 | 2017-10-19 | Arbutus Biopharma Corporation | Targeted nucleic acid conjugate compositions |
-
2021
- 2021-10-08 CA CA3198406A patent/CA3198406A1/en active Pending
- 2021-10-08 IL IL302000A patent/IL302000A/en unknown
- 2021-10-08 JP JP2023521602A patent/JP2023546369A/ja active Pending
- 2021-10-08 EP EP21878681.2A patent/EP4225322A4/en active Pending
- 2021-10-08 CN CN202511141891.7A patent/CN121108223A/zh active Pending
- 2021-10-08 US US18/030,968 patent/US20240083934A1/en active Pending
- 2021-10-08 AU AU2021359017A patent/AU2021359017A1/en active Pending
- 2021-10-08 MX MX2023004170A patent/MX2023004170A/es unknown
- 2021-10-08 CN CN202511141817.5A patent/CN121108222A/zh active Pending
- 2021-10-08 WO PCT/US2021/054318 patent/WO2022076922A1/en not_active Ceased
- 2021-10-08 KR KR1020237015687A patent/KR20230113285A/ko active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP4225322A4 (en) | 2024-12-11 |
| IL302000A (en) | 2023-06-01 |
| WO2022076922A1 (en) | 2022-04-14 |
| CA3198406A1 (en) | 2022-04-14 |
| CN121108223A (zh) | 2025-12-12 |
| AU2021359017A9 (en) | 2024-09-26 |
| CN121108222A (zh) | 2025-12-12 |
| KR20230113285A (ko) | 2023-07-28 |
| AU2021359017A1 (en) | 2023-05-25 |
| JP2023546369A (ja) | 2023-11-02 |
| US20240083934A1 (en) | 2024-03-14 |
| EP4225322A1 (en) | 2023-08-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2023004170A (es) | Compuestos y oligonucleótidos derivados de n-acetilgalactosamina (galnac). | |
| MX2022010425A (es) | Metodos de tratamiento de enfermedades asociadas a los receptores de estrogenos. | |
| EP4491234A3 (en) | Multi-specific binding proteins for activation of natural killer cells and therapeutic uses thereof to treat cancer | |
| MX2022011550A (es) | Composiciones y métodos para inhibir la expresión de angptl3. | |
| PH12021552829A1 (en) | T cell manufacturing compositions and methods | |
| WO2019094642A8 (en) | T cell manufacturing compositions and methods | |
| WO2019166412A9 (en) | Modulation of pla2-g1b in therapy | |
| SA523442921B1 (ar) | جزيئات ربط علاجية | |
| PH12023550032A1 (en) | Tubulysins and protein-tubulysin conjugates | |
| MX2023005591A (es) | Metodos de tratamiento de enfermedades y trastornos. | |
| NZ588435A (en) | Use of a polypeptide with an angiotensin-converting enzyme 2 (ACE2) activity for treating tumours (with the exception of lung cancer) | |
| WO2022218941A3 (en) | Compositions and methods for inhibiting ketohexokinase (khk) | |
| ZA202304965B (en) | Combination therapy for treating cancer | |
| WO2023018722A3 (en) | Compositions and methods for treating autoimmune diseases and cancers by targeting igsf8 | |
| EP4353318A3 (en) | Compositions and methods for targeting and killing alpha-v beta-3-positive cancer stem cells (cscs) and treating drug resistant cancers | |
| MX2022015966A (es) | Anticuerpos y metodos para tratar enfermedades asociadas a claudina. | |
| MX2024001211A (es) | Proteinas de fusion fc heterodimericas il15/il15r alfa para el tratamiento de tipos de cancer de sangre. | |
| WO2020142740A8 (en) | Treatment of sjogren's disease with nuclease fusion proteins | |
| MX2025004473A (es) | Novedosos anticuerpos anti-napi2b y conjugados-anticuerpo-droga basados en ellos, metodos terapeuticos y usos de los mismos | |
| MX2025006068A (es) | Proteina de union cldn18.2/4-1bb y su uso medico | |
| MX2023006087A (es) | Formulaciones liofilizadas de tegavivint. | |
| WO2024026308A3 (en) | COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF THE SIGNAL REGULATORY PROTEIN ALPHA (SIRPα) GENE | |
| MX2021013351A (es) | Terapias de combinacion. | |
| MX2025006565A (es) | Terapia contra el cancer con capivasertib y fulvestrant | |
| MX2023012510A (es) | Vesiculas extracelulares cargadas con biomoleculas. |